PKA phosphorylation redirects ERα to promoters of a unique gene set to induce tamoxifen resistance

Oncogene

Volumn 32, Issue 30, 2013, Pages 3543-3551

  De Leeuw, R ^a   Flach, K ^a   Toaldo, C Bentin ^a   Alexi, X ^a   Canisius, S ^a   Neefjes, J ^a   Michalides, R ^a   Zwart, W ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Breast cancer; ChIP seq; Estrogen receptor; Myc; Protein kinase A; Tamoxifen resistance

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; ESTROGEN RECEPTOR ALPHA; TAMOXIFEN;

ARTICLE; BINDING SITE; BREAST CANCER; CANCER PATIENT; CANCER RESISTANCE; CELL PROLIFERATION; CHROMATIN; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DRUG RESISTANCE, NEOPLASM; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; TAMOXIFEN;

EID: 84880918115     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.361     Document Type: Article

References (58)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Cancer incidence and mortality worldwide. IARC CancerBase No. 10 2010.
2. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874. (Pubitemid 32878711)
3. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998; 95: 927-937. (Pubitemid 29019045)
4. Robertson JF. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective. Cancer Treat Rev 2004; 30: 695-706. (Pubitemid 39497155)
5. Holm C, Kok M, Michalides R, Fles R, Koornstra RH, Wesseling J et al. Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancer. J Pathol 2009; 217: 372-379.
6. Kok M, Zwart W, Holm C, Fles R, Hauptmann M, Van't Veer LJ et al. PKA-induced phosphorylation of ERalpha at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer. Breast Cancer Res Treat 2011; 125: 1-12.
7. Bostner J, Skoog L, Fornander T, Nordenskjold B, Stal O. Estrogen receptor-alpha phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer. Clin Cancer Res 2010; 16: 1624-1633.
8. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 2008; 68: 826-833. (Pubitemid 351206760)
9. Fan P, Wang J, Santen RJ, Yue W. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. Cancer Res 2007; 67: 1352-1360.
10. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004; 96: 926-935. (Pubitemid 38868139)
11. Riggins RB, Schrecengost RS, Guerrero MS, Bouton AH. Pathways to tamoxifen resistance. Cancer Lett 2007; 256: 1-24. (Pubitemid 47333324)
12. Kirkegaard T, Witton CJ, McGlynn LM, Tovey SM, Dunne B, Lyon A et al. AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 2005; 207: 139-146. (Pubitemid 41404144)
13. Gee JM, Robertson JF, Ellis IO, Nicholson RI. Phosphorylation of ERK1/2 mitogenactivated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 2001; 95: 247-254. (Pubitemid 32592092)
14. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995; 270: 1491-1494.
15. Rayala SK, Molli PR, Kumar R. Nuclear p21-activated kinase 1 in breast cancer packs off tamoxifen sensitivity. Cancer Res 2006; 66: 5985-5988.
16. Rayala SK, Talukder AH, Balasenthil S, Tharakan R, Barnes CJ, Wang RA et al. P21-activated kinase 1 regulation of estrogen receptor-alpha activation involves serine 305 activation linked with serine 118 phosphorylation. Cancer Res 2006; 66: 1694-1701. (Pubitemid 43259954)
17. Michalides R, Griekspoor A, Balkenende A, Verwoerd D, Janssen L, Jalink K et al. Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. Cancer Cell 2004; 5: 597-605. (Pubitemid 38748921)
18. de Leeuw R, Neefjes J, Michalides RA. Role for Estrogen Receptor Phosphorylation in the Resistance to Tamoxifen. Int J Breast Cancer 2011; 2011: 232435.
19. Skliris GP, Rowan BG, Al Dhaheri M, Williams C, Troup S, Begic S et al. Immunohistochemical validation of multiple phospho-specific epitopes for estrogen receptor alpha (ERalpha) in tissue microarrays of ERalpha positive human breast carcinomas. Breast Cancer Res Treat 2009; 118: 443-453.
20. Skliris GP, Nugent ZJ, Rowan BG, Penner CR, Watson PH, Murphy LC. A phosphorylation code for oestrogen receptor-alpha predicts clinical outcome to endocrine therapy in breast cancer. Endocr Relat Cancer 2010; 17: 589-597.
21. Zwart W, Griekspoor A, Berno V, Lakeman K, Jalink K, Mancini M et al. PKAinduced resistance to tamoxifen is associated with an altered orientation of ERalpha towards co-activator SRC-1. EMBO J 2007; 26: 3534-3544. (Pubitemid 47236876)
22. Dudek P, Picard D. Genomics of signaling crosstalk of estrogen receptor alpha in breast cancer cells. PLoS One 2008; 3: e1859.
23. Miller WR. Regulatory subunits of PKA and breast cancer. Ann NY Acad Sci 2002; 968: 37-48. (Pubitemid 34721870)
24. Wu RC, Qin J, Yi P, Wong J, Tsai SY, Tsai MJ et al. Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways. Mol Cell 2004; 15: 937-949. (Pubitemid 39277990)
25. Yi P, Feng Q, Amazit L, Lonard DM, Tsai SY, Tsai M et al. Atypical protein kinase C regulates dual pathways for degradation of the oncogenic coactivator SRC-3/AIB1. Mol Cell 2008; 29: 465-476. (Pubitemid 351291678)
26. Carascossa S, Dudek P, Cenni B, Briand PA, Picard D. CARM1 mediates the ligandindependent and tamoxifen-resistant activation of the estrogen receptor alpha by cAMP. Genes Dev 2010; 24: 708-719.
27. Lupien M, Eeckhoute J, Meyer CA, Krum SA, Rhodes DR, Liu XS et al. Coactivator function defines the active estrogen receptor alpha cistrome. Mol Cell Biol 2009; 29: 3413-3423.
28. Lupien M, Meyer CA, Bailey ST, Eeckhoute J, Cook J, Westerling T et al. Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance. Genes Dev 2010; 24: 2219-2227.
29. Reiner GC, Katzenellenbogen BS. Characterization of estrogen and progesterone receptors and the dissociated regulation of growth and progesterone receptor stimulation by estrogen in MDA-MB-134 human breast cancer cells. Cancer Res 1986; 46: 1124-1131. (Pubitemid 16048242)
30. Al Dhaheri MH, Rowan BG. Protein kinase A exhibits selective modulation of estradiol-dependent transcription in breast cancer cells that Is associated with decreased ligand binding, altered estrogen receptor {alpha} promoter interaction, and changes in receptor phosphorylation. Mol Endocrinol 2007; 21: 439-456. (Pubitemid 46184894)
31. Bossis I, Stratakis CA. Minireview: PRKAR1A: normal and abnormal functions. Endocrinology 2004; 145: 5452-5458. (Pubitemid 39564583)
32. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007; 25: 1239-1246. (Pubitemid 46640570)
33. Buffa FM, Camps C, Winchester L, Snell CE, Gee HE, Sheldon H et al. microRNAassociated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res 2011; 71: 5635-5645.
34. Chen D, Pace PE, Coombes RC, Ali S. Phosphorylation of human estrogen receptor alpha by protein kinase A regulates dimerization. Mol Cell Biol 1999; 19: 1002-1015. (Pubitemid 29046844)
35. Schmidt D, Wilson MD, Spyrou C, Brown GD, Hadfield J, Odom DT. ChIP-seq: using high-throughput sequencing to discover protein-DNA interactions. Methods 2009; 48: 240-248.
36. Robinson JL, Macarthur S, Ross-Innes CS, Tilley WD, Neal DE, Mills IG et al. Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J 2011; 30: 3019-3027.
37. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J et al. Genome-wide analysis of estrogen receptor binding sites. Nat Genet 2006; 38: 1289-1297. (Pubitemid 44646291)
38. Madak-Erdogan Z, Lupien M, Stossi F, Brown M, Katzenellenbogen BS. Genomic collaboration of estrogen receptor alpha and extracellular signal-regulated kinase 2 in regulating gene and proliferation programs. Mol Cell Biol 2011; 31: 226-236.
39. Miller TW, Balko JM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M et al. A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance. Clin Cancer Res 2011; 17: 2024-2034.
40. Musgrove EA, Sergio CM, Loi S, Inman CK, Anderson LR, Alles MC et al. Identification of functional networks of estrogen-and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer. PLoS One 2008; 3: e2987.
41. Louie MC, McClellan A, Siewit C, Kawabata L. Estrogen receptor regulates E2F1 expression to mediate tamoxifen resistance. Mol Cancer Res 2010; 8: 343-352.
42. Fullwood MJ, Liu MH, Pan YF, Liu J, Xu H, Mohamed YB et al. An oestrogenreceptor-alpha-bound human chromatin interactome. Nature 2009; 462: 58-64.
43. Wang C, Mayer JA, Mazumdar A, Fertuck K, Kim H, Brown M et al. Estrogen induces c-myc gene expression via an upstream enhancer activated by the estrogen receptor and the AP-1 transcription factor. Mol Endocrinol 2011; 25: 1527-1538.
44. Inoue A, Omoto Y, Yamaguchi Y, Kiyama R, Hayashi SI. Transcription factor EGR3 is involved in estrogen-signaling pathway in breast cancer cells. J Mol Endocrinol 2004; 32: 649-661. (Pubitemid 38877679)
45. Suzuki T, Inoue A, Miki Y, Moriya T, Akahira J, Ishida T et al. Early growth responsive gene 3 in human breast carcinoma: a regulator of estrogen-meditated invasion and a potent prognostic factor. Encocr Relat Cancer 2007; 14: 279-292. (Pubitemid 47242629)
46. Frietze S, Lupien M, Silver PA, Brown M. CARM1 regulates estrogen-stimulated breast cancer growth through up-regulation of E2F1. Cancer Res 2008; 68: 301-306. (Pubitemid 351380132)
47. Callero MA, Loaiza-Pérez AI. The role of aryl hydrocarbon receptor and crosstalk with estrogen receptor in response of breast cancer cells to the novel antitumor agents benzothiazoles and aminoflavone. Int J Breast Cancer 2011; 2011: 923250.
48. Madak-Erdogan Z, Katzenellenbogen BS. Aryl hydrocarbon receptor modulation of estroge receptor a-mediated gene regulation by a multimeric chromatin complex involving the two receptors and the coregulator RIP140. Toxicol Sci 2012; 125: 401-411.
49. Chandra V, Huang P, Hamuro Y, Raghuram S, Wang Y, Burris TP et al. Structure of the intact PPAR-gamma-RXR-alpha nuclear receptor complex on DNA. Nature 2008; 456: 350-356.
50. Krum SA, Miranda-Carboni GA, Lupien M, Eeckhoute J, Carroll JS, Brown M. Unique ERalpha cistromes control cell type-specific gene regulation. Mol Endocrinol 2008; 22: 2393-2406.
51. Welboren WJ, van Driel MA, Janssen-Megens EM, van Heeringen SJ, Sweep FC, Span PN et al. ChIP-Seq of ERalpha and RNA polymerase II defines genes differentially responding to ligands. EMBO J 2009; 28: 1418-1428.
52. Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet 2009; 43: 27-33.
53. Carroll JS, Liu XS, Brodsky AS, Li W, Meyer CA, Szary AJ et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 2005; 15: 33-43. (Pubitemid 40977938)
54. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE et al. Modelbased analysis of ChIP-Seq (MACS). Genome Biol 2008; 9: R137.
55. Zang C, Schones DE, Zeng C, Cui K, Zhao K, Peng W. A clustering approach for identification of enriched domains from histone modification ChIP-Seq data. Bioinformatics 2009; 25: 1952-1958.
56. Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 1995; 92: 7297-7301.
57. Ji X, Li W, Song J, Wei L, Liu XS. CEAS: cis-regulatory element annotation system. Nucleic Acids Res 2006; 34: W551-W554. (Pubitemid 44529830)
58. He HH, Meyer CA, Shin H, Bailey ST, Wei G, Wang Q et al. Nucleosome dynamics define transcriptional enhancers. Nat Genet 2010; 42: 343-347.